Sonnet BioTherapeutics Holdings, Inc. has announced an expansion of its Phase 1 SB101 clinical trial of SON-1010, a candidate immunotherapy, to evaluate its effectiveness in combination with the ...

WEST LAFAYETTE, Ind. – A multidisciplinary team of researchers led by Steve Son, a professor of mechanical engineering at Purdue University, has received a $7.5 million grant by the Air Force Office ...

Continued progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC) Executed licensing agreement to support initiation of a Phase 2 ...

Erin Eun-Young Ahn, Ph.D., Associate Professor, Molecular and Cellular Pathology, was recently awarded an R01 from the National Cancer Institute based on her project submission, titled, "SON-mediated ...

Sonnet's lead product, SON-1010 (IL12-F H AB), is being evaluated in combination with atezolizumab (Tecentriq ®) in patients with advanced platinum-resistant ovarian cancer (PROC) (SB221) Topline ...

Expectant mothers who get vaccinated to protect their newborns against respiratory syncytial virus (RSV) are not putting themselves or their babies at risk, new research affirms. Photo by Adobe ...

PRINCETON, NJ / ACCESSWIRE / February 1, 2021 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that it has ...